GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

TCRX · Jun 30, 2024

TScan Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0000950170-24-095066General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

5680.60% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

160.82% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-4892.72% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

-82.97% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-6364.55% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

5014.37% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

434.33% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Dec 31, 20230/7 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20246/7 normalizedLevel 3 Mar 31, 20256/7 normalizedLevel 3 Jun 30, 20256/7 normalizedLevel 3 Sep 30, 20256/7 normalizedLevel 3 Dec 31, 20257/7 normalizedLevel 3 Mar 31, 20267/7 normalizedLevel 3 Jun 30, 20267/7 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Increased

Previous: 5343.82%
Current: 5680.60%
Delta: 336.78%

Capex Intensity Increased

Previous: 124.56%
Current: 160.82%
Delta: 36.26%

Cash Generation Increased

Previous: -5170.85%
Current: -4892.72%
Delta: 278.12%

Growth Increased

Previous: -91.68%
Current: -82.97%
Delta: 8.71%

Profitability Decreased

Previous: -5542.93%
Current: -6364.55%
Delta: -821.62%

R And D Intensity Increased

Previous: 4391.70%
Current: 5014.37%
Delta: 622.67%

Sbc Intensity Increased

Previous: 350.53%
Current: 434.33%
Delta: 83.80%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · TCRX Fundamental State →Has State · TScan Therapeutics, Inc. →Transitioned To · TCRX Fundamental State →Transitioned To · TCRX BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · TCRX CAPEX_INTENSITY_INCREASED →Transitioned To · TCRX CASH_GENERATION_INCREASED →Transitioned To · TCRX GROWTH_INCREASED →Transitioned To · TCRX PROFITABILITY_DECREASED →Transitioned To · TCRX R_AND_D_INTENSITY_INCREASED →Transitioned To · TCRX SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.